Clinical trials: Zoster Varicella
Herpes Zoster
A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of 3 dose levels of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50…
- Trial name
- NCT07205796
- Testing
- HZ Vaccine (IN001), Shingrix
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
Chickenpox
Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine
The purpose of this study is to observe the occurrence of adverse events, seroconversion rate and geometric mean titres(GMTs) of 2 doses of live attenuated varicella vaccine.
- Trial name
- NCT01817270
- Testing
- Live Attenuated Varicella Vaccine
- Where
- China
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- Changchun Keygen Biological Products Co., Ltd.
Rheumatoid Arthritis, Spondylitis, Ankylosing
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
Introduction: Patients with autoimmune rheumatic diseases (ARDs), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PAs), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), primary…
- Conditions
- Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis, Systemic Lupus Erythematosus
- Trial name
- RZVRheum (NCT05879419)
- Testing
- Recombinant Herpes Zoster Vaccine (RZV), MTX Discontinuation, MMF Discontinuation
- Where
- Brazil
- Volunteers
- 2,005 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Post Herpetic Neuralgia, Herpes Zoster
Treatment of Chronic Postherpetic Pain With Fat Grafting
This study evaluates the possible beneficial effect of fat grafting for post herpetic neuralgia.
- Trial name
- NCT03584061
- Testing
- Fat grafting
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Meningococcal Meningitis, Measles
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
This clinical trial will evaluate the safety of two injections of Menactra® Vaccine in subjects at 9 months and at 12 months of age when the second dose is given concomitantly with other pediatric vaccines routinely administered…
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00483574
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV)
- Where
- 79 sites in United States, Chile
- Volunteers
- 1,378 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Herpes Zoster (HZ)
Multimodal Nerve Block and Pulse Radiofrequency for Acute Herpes Zoster Pain
The primary objective of this clinical trial is to evaluate the efficacy of liposomal bupivacaine and ropivacaine in the treatment of pain associated with herpes zoster (shingles).
- Trial name
- NCT06798662
- Testing
- Ultrasound-Guided Pulsed Radiofrequency (PRF), Intercostal nerve block (2% ropivacaine or 133 mg of liposomal bupivacaine), Paravertebral (PVB) Block (2% ropivacaine or 133 mg of liposomal bupivacaine)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiaguang Duan
Herpes Zoster
Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)
PRIMARY OBJECTIVES Two co-primary objectives are: To demonstrate that the immunogenicity of ZOSTAVAX administered by intramuscular route (IM) is non-inferior to ZOSTAVAX administered by subcutaneous route (SC) To demonstrate that…
- Trial name
- NCT01391546
- Testing
- ZOSTAVAX
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chickenpox, Herpes Zoster
Immune Response to Varicella-Zoster Vaccination and Infection
Background: The common varicella-zoster virus causes both chickenpox and shingles. Both diseases cause rashes, but they can also have complications such as bacterial infections of the skin, pneumonia, or eye disease.
- Trial name
- NCT00921999
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Varicella Zoster Virus Infection, Herpes Simplex Virus Infection
Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir
A new paediatric formulation (oral liquid) has been developed for flexible and accurate dosing of valacyclovir in children. To establish the bioavailability of this new formulation, healthy volunteers will be exposed to the new…
- Trial name
- VALID-I (NCT01689285)
- Testing
- valacyclovir tablet, valacyclovir oral solution
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Herpes Zoster (HZ), Shingles
A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine
The goal of this clinical trial is to assess the safety and immunogenicity of a self-replicating (sr) RNA-based vaccine, JCXH-105, in the prevention of Shingles (Herpes Zoster) Participant will be randomized to receive either…
- Conditions
- Herpes Zoster (HZ), Shingles, Infectious Disease
- Trial name
- JCXH-105 (NCT05871541)
- Testing
- JCXH-105, Active Control (Shingrix)
- Where
- 3 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Immorna Biotherapeutics, Inc.
Herpes Zoster (HZ)
A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals
The purpose of this clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above.
- Trial name
- NCT06932523
- Testing
- Recombinant herpes zoster vaccine with low-dose adjuvant, Recombinant herpes zoster vaccine with high-dose adjuvant, Low-dose adjuvant
- Where
- China
- Volunteers
- 645 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Herpes Zoster
Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years
The purpose of this study was to assess vaccine efficacy (VE), ability to generate immune response and safety of two doses of the recombinant subunit zoster vaccine (RZV) for prevention of Herpes Zoster (HZ) in Chinese adults…
- Trial name
- NCT04869982
- Testing
- RZV
- Where
- 6 sites in China
- Volunteers
- 6,138 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis
Effect of MTX Discontinuation on Shingrix Response in RA
The goal of this clinical trial is to learn if methotrexate discontinuation affect on immunogeneity of shingrix in RA patients. The main questions it aims to answer are: Discontinuation of methotrexate after shingrix immunization…
- Trial name
- NCT06574594
- Testing
- Methotrexate
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Konkuk University Medical Center
Shingles
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
The purpose of this study is to determine the immunity (the body's protection) against shingles after receiving two doses of an investigational vaccine or placebo (a look alike vaccine with no active ingredients).
- Trial name
- NCT00109122
- Testing
- zoster vaccine live (Oka/Merck)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster, Shingles
ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)
This study will evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ in Korean adults. Approximately 180 herpes zoster history negative subjects ≥ 50 years of age will be enrolled in the study.
- Trial name
- NCT01556451
- Testing
- Zoster Vaccine Live
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
SARS-CoV-2 Infection, Varicella
Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines
Eligible participants were randomly assigned (1:1:1), using block randomization stratified, to either 3 groups. Group 1 will be immunized inactivated SARS-CoV-2 vaccine and varicella vaccine in day 0 followed by…
- Conditions
- SARS-CoV-2 Infection, Varicella, Measles, Mumps
- Trial name
- NCT05952505
- Testing
- Inactivated SARS-CoV-2 vaccine coadministered with vricella vaccine, Inactivated SARS-CoV-2 vaccine coadministered with MMR, Inactivated SARS-CoV-2 vaccine administered alone
- Where
- China
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Shanghai Municipal Center for Disease Control and Prevention
Postherpetic Neuralgia
New Topical Treatment for Continued Pain After Shingles
Shingles is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chicken pox. Some people experience continued pain even after the shingles rash and blisters have healed; this pain is known as…
- Trial name
- NCT00566904
- Testing
- Epikeia coatings with aspirin, Epikeia coatings with lidocaine, Epikeia coatings alone
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Biomedical Development Corporation
Herpes Zoster (HZ)
Obesity and Obesity-Related Factors and Risk of Herpes Zoster (Shingles) and Postherpetic Neuralgia
The investigators' objectives are to examine the longitudinal association of obesity and obesity-related factors and risk of incident herpes zoster (HZ), also known as shingles, and the longitudinal association of obesity and…
- Trial name
- NCT06638177
- Volunteers
- 200,000 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Vaccine-Preventable Diseases, Herpes Zoster
A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine
This clinical trial is to study protective efficacy and safety of a recombinant herpes zoster vaccine (LZ901) and sponsored by Beijing Luzhu Biotechnology Co., Ltd.
- Trial name
- NCT06088745
- Testing
- Recombinant Herpes Zoster Vaccine
- Where
- China
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Beijing Luzhu Biotechnology Co., Ltd.
Herpes Zoster, Pneumococcal Infection
ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)
The purpose of this study is to determine whether Zoster Vaccine Live and Pneumococcal Vaccine, polyvalent are as well tolerated and immunogenic when the vaccines are given together (in different body sites), as when they are…
- Trial name
- NCT00535730
- Testing
- Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™, Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23
- Volunteers
- 473 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC